Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
CJC-1295 Peptide
GHRH analog often paired with Ipamorelin for pulsatile support.
What is CJC-1295?
CJC-1295 is a growth hormone axis peptide studied for endogenous gh pulse amplitude and igf-1 elevation. Below is an educational overview of CJC-1295 peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
CJC-1295 in plain language
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue studied for its effect on pulsatile growth hormone and IGF-1 levels.
- Classification: available through licensed compounding pharmacies in some contexts; not an FDA-approved drug product.
- Mechanism: binds the GHRH receptor in the anterior pituitary to increase growth hormone release.
- Commonly researched alongside: ipamorelin, a ghrelin-receptor agonist with a complementary mechanism.
- Administration in research: subcutaneous injection; the DAC-modified version has a substantially longer half-life than the non-DAC form.
- Evidence level: early-phase human pharmacokinetic studies exist; long-term outcome data do not.
- Regulatory note: prohibited in sport under WADA category S2.
Machine-readable version: /peptide/cjc-1295/summary
CJC-1295 Mechanism of Action
A synthetic analog of growth hormone-releasing hormone (GHRH). The non-DAC version has a short half-life that preserves pulsatile GH release, while DAC variants extend the half-life via albumin binding. Research focuses on stimulating endogenous GH and IGF-1 production via the pituitary.
CJC-1295 Research Areas & Benefits
CJC-1295 Dosage & Common Research Protocols
Combined with Ipamorelin in research to layer GHRH + ghrelin-mimetic signaling for pulsatile GH release.
Studied as longer-acting GH elevation in clinical pharmacology trials.
Protocols summarized for educational reference from published research. Not dosing guidance.
CJC-1295 Studies & Cited Research
Sustained pharmacological GH activity in healthy adults via DAC technology
Established prolonged GH/IGF-1 elevation from single subcutaneous doses.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
GHRH analogs and the GH-IGF-1 axis
Mechanistic review of GHRH-analog pharmacology.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
CJC-1295 Side Effects & Safety Considerations
- •GH-axis manipulation may affect glucose tolerance.
- •Banned in competitive sport (WADA).
- •Requires physician oversight in any therapeutic context.
Common questions about CJC-1295
Research stacks featuring CJC-1295
More Performance peptides · See all 14
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Key references for CJC-1295
Primary sources reviewed by the Peptides.cafe research team. Links open the original PubMed record, journal listing, or regulatory notice.
- [1]Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting GHRH analogJournal of Clinical Endocrinology & Metabolism · 2006
Primary human pharmacology data for GH/IGF-1 response and half-life extension.
- [2]Growth hormone-releasing hormone analogs: therapeutic potential and limitationsEndocrine Reviews · 2019
Context on where GHRH analogues sit relative to approved endocrine therapy.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.